<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7438974\results\search\disease\results.xml">
  <result pre="pmcid: 7438974S0168-8278(20)30220-8 doi: 10.1016/j.jhep.2020.04.008 : Article The global prevalence of" exact="hepatitis D" post="virus infection: Systematic review and meta-analysis StockdaleAlexander J.12KreuelsBenno34HenrionMarc Y.R.25GiorgiEmanuele6KyomuhangiIrene6de"/>
  <result pre="[4], [5], [6], [7], [8], âˆ—Corresponding author. Address: Institute of" exact="Infection" post="and Global Health, University of Liverpool, Ronald Ross Building,"/>
  <result pre="Aims There are uncertainties about the epidemic patterns of HDV" exact="infection" post="and its contribution to the burden of liver disease."/>
  <result pre="patterns of HDV infection and its contribution to the burden" exact="of liver" post="disease. We estimated the global prevalence of HDV infection"/>
  <result pre="of HDV infection and its contribution to the burden of" exact="liver disease." post="We estimated the global prevalence of HDV infection and"/>
  <result pre="of liver disease. We estimated the global prevalence of HDV" exact="infection" post="and explored its contribution to the development of cirrhosis"/>
  <result pre="HDV infection and explored its contribution to the development of" exact="cirrhosis" post="and hepatocellular carcinoma (HCC) among HBsAg-positive people. Methods We"/>
  <result pre="and explored its contribution to the development of cirrhosis and" exact="hepatocellular carcinoma" post="(HCC) among HBsAg-positive people. Methods We searched Pubmed, EMBASE"/>
  <result pre="explored its contribution to the development of cirrhosis and hepatocellular" exact="carcinoma" post="(HCC) among HBsAg-positive people. Methods We searched Pubmed, EMBASE"/>
  <result pre="We searched Pubmed, EMBASE and Scopus for studies reporting on" exact="total" post="or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was"/>
  <result pre="population size. The population attributable fraction (PAF) of HDV to" exact="cirrhosis" post="and HCC among HBsAg-positive people was estimated using random"/>
  <result pre="people, preliminary PAF estimates of HDV were 18% (10â€&quot;26) for" exact="cirrhosis" post="and 20% (8â€&quot;33) for HCC. Conclusions An estimated 12"/>
  <result pre="areas and populations. HDV is a significant contributor to HBV-associated" exact="liver disease." post="More quality data are needed to improve the precision"/>
  <result pre="combined all available studies to estimate how many people with" exact="hepatitis" post="B also have hepatitis D, a viral infection that"/>
  <result pre="to estimate how many people with hepatitis B also have" exact="hepatitis D," post="a viral infection that only affects people with hepatitis"/>
  <result pre="many people with hepatitis B also have hepatitis D, a" exact="viral infection" post="that only affects people with hepatitis B. About 1"/>
  <result pre="people with hepatitis B also have hepatitis D, a viral" exact="infection" post="that only affects people with hepatitis B. About 1"/>
  <result pre="hepatitis D, a viral infection that only affects people with" exact="hepatitis" post="B. About 1 in 22 people with hepatitis B"/>
  <result pre="people with hepatitis B. About 1 in 22 people with" exact="hepatitis" post="B also have hepatitis D, increasing to 1 in"/>
  <result pre="About 1 in 22 people with hepatitis B also have" exact="hepatitis D," post="increasing to 1 in 6 when considering people with"/>
  <result pre="D, increasing to 1 in 6 when considering people with" exact="liver disease." post="Hepatitis D may cause about 1 in 6 of"/>
  <result pre="to 1 in 6 when considering people with liver disease." exact="Hepatitis" post="D may cause about 1 in 6 of the"/>
  <result pre="may cause about 1 in 6 of the cases of" exact="cirrhosis" post="and 1 in 5 of the cases of liver"/>
  <result pre="cases of cirrhosis and 1 in 5 of the cases" exact="of liver" post="cancer that occur in people with hepatitis B. Hepatitis"/>
  <result pre="of cirrhosis and 1 in 5 of the cases of" exact="liver cancer" post="that occur in people with hepatitis B. Hepatitis D"/>
  <result pre="cirrhosis and 1 in 5 of the cases of liver" exact="cancer" post="that occur in people with hepatitis B. Hepatitis D"/>
  <result pre="the cases of liver cancer that occur in people with" exact="hepatitis" post="B. Hepatitis D is an important contributor to the"/>
  <result pre="of liver cancer that occur in people with hepatitis B." exact="Hepatitis" post="D is an important contributor to the global burden"/>
  <result pre="Hepatitis D is an important contributor to the global burden" exact="of liver" post="disease. Graphical abstract Highlights â€¢HDV infection is common among"/>
  <result pre="D is an important contributor to the global burden of" exact="liver disease." post="Graphical abstract Highlights â€¢HDV infection is common among HBsAg-positive"/>
  <result pre="the global burden of liver disease. Graphical abstract Highlights â€¢HDV" exact="infection" post="is common among HBsAg-positive people worldwide. â€¢Among HBsAg-positive people,"/>
  <result pre="have HCV or HIV. â€¢HDV causes an estimated 18% of" exact="cirrhosis" post="and 20% of HCC associated with hepatitis B. Keywords"/>
  <result pre="estimated 18% of cirrhosis and 20% of HCC associated with" exact="hepatitis" post="B. Keywords Hepatitis D Hepatitis delta virus Hepatitis B"/>
  <result pre="cirrhosis and 20% of HCC associated with hepatitis B. Keywords" exact="Hepatitis" post="D Hepatitis delta virus Hepatitis B Liver cirrhosis Carcinoma"/>
  <result pre="20% of HCC associated with hepatitis B. Keywords Hepatitis D" exact="Hepatitis" post="delta virus Hepatitis B Liver cirrhosis Carcinoma Hepatocellular Prevalence"/>
  <result pre="associated with hepatitis B. Keywords Hepatitis D Hepatitis delta virus" exact="Hepatitis" post="B Liver cirrhosis Carcinoma Hepatocellular Prevalence Epidemiology Meta-analysis See"/>
  <result pre="B. Keywords Hepatitis D Hepatitis delta virus Hepatitis B Liver" exact="cirrhosis" post="Carcinoma Hepatocellular Prevalence Epidemiology Meta-analysis See Editorial, pages 493â€&quot;495"/>
  <result pre="Keywords Hepatitis D Hepatitis delta virus Hepatitis B Liver cirrhosis" exact="Carcinoma" post="Hepatocellular Prevalence Epidemiology Meta-analysis See Editorial, pages 493â€&quot;495 Introduction"/>
  <result pre="Hepatitis D Hepatitis delta virus Hepatitis B Liver cirrhosis Carcinoma" exact="Hepatocellular" post="Prevalence Epidemiology Meta-analysis See Editorial, pages 493â€&quot;495 Introduction Globally,"/>
  <result pre="Hepatocellular Prevalence Epidemiology Meta-analysis See Editorial, pages 493â€&quot;495 Introduction Globally," exact="chronic" post="infection with the HBV is an important cause of"/>
  <result pre="Prevalence Epidemiology Meta-analysis See Editorial, pages 493â€&quot;495 Introduction Globally, chronic" exact="infection" post="with the HBV is an important cause of liver-related"/>
  <result pre="are chronically infected with HBV and are at risk of" exact="cirrhosis" post="and hepatocellular carcinoma (HCC).1,2 The proportion of cirrhosis attributable"/>
  <result pre="infected with HBV and are at risk of cirrhosis and" exact="hepatocellular carcinoma" post="(HCC).1,2 The proportion of cirrhosis attributable to HBV varies"/>
  <result pre="with HBV and are at risk of cirrhosis and hepatocellular" exact="carcinoma" post="(HCC).1,2 The proportion of cirrhosis attributable to HBV varies"/>
  <result pre="risk of cirrhosis and hepatocellular carcinoma (HCC).1,2 The proportion of" exact="cirrhosis" post="attributable to HBV varies geographically according to HBV epidemiology,"/>
  <result pre="on HBV for propagation.5 It uses the HBsAg as a" exact="viral" post="envelope and shares the same hepatocyte receptor for viral"/>
  <result pre="a viral envelope and shares the same hepatocyte receptor for" exact="viral" post="entry.6 HDV is among the smallest of viruses capable"/>
  <result pre="HBV co-infection with HDV is the most severe form of" exact="viral" post="hepatitis.5 HDV transmission follows 2 patterns. Infection occurring simultaneously"/>
  <result pre="severe form of viral hepatitis.5 HDV transmission follows 2 patterns." exact="Infection" post="occurring simultaneously with HBV can cause extensive hepatic necrosis"/>
  <result pre="hepatic necrosis and manifest as a severe or even fulminant" exact="hepatitis" post="with a high case fatality rate.6 With recovery, simultaneous"/>
  <result pre="hepatitis with a high case fatality rate.6 With recovery, simultaneous" exact="infection" post="in adults usually results in clearance of both viruses.5"/>
  <result pre="results in clearance of both viruses.5 Super-infection of persons with" exact="chronic" post="HBV infection typically results in HDV persistence, leading to"/>
  <result pre="clearance of both viruses.5 Super-infection of persons with chronic HBV" exact="infection" post="typically results in HDV persistence, leading to accelerated progression"/>
  <result pre="typically results in HDV persistence, leading to accelerated progression to" exact="cirrhosis" post="and an increased risk of HCC relative to chronic"/>
  <result pre="to cirrhosis and an increased risk of HCC relative to" exact="chronic" post="HBV infection alone.7 Due to variation in awareness and"/>
  <result pre="and an increased risk of HCC relative to chronic HBV" exact="infection" post="alone.7 Due to variation in awareness and incomplete testing"/>
  <result pre="chronic HBV infection alone.7 Due to variation in awareness and" exact="incomplete" post="testing among HBsAg-positive people,8 issues with standardisation of confirmatory"/>
  <result pre="HDV may therefore have an under-recognised role in the causation" exact="of liver" post="disease and liver-related deaths. Estimating HDV prevalence and the"/>
  <result pre="may therefore have an under-recognised role in the causation of" exact="liver disease" post="and liver-related deaths. Estimating HDV prevalence and the relative"/>
  <result pre="therefore have an under-recognised role in the causation of liver" exact="disease" post="and liver-related deaths. Estimating HDV prevalence and the relative"/>
  <result pre="Estimating HDV prevalence and the relative contribution of HDV towards" exact="liver disease," post="including among general populations and specific population groups, is"/>
  <result pre="identify and collate all globally available epidemiological data on HDV" exact="infection" post="from January 1998 to January 2019. We aimed to"/>
  <result pre="2019. We aimed to describe the geographic distribution of HDV" exact="infection" post="and to produce regional estimates of HDV infection among"/>
  <result pre="of HDV infection and to produce regional estimates of HDV" exact="infection" post="among general populations, individuals attending hepatology clinics, and selected"/>
  <result pre="error. We further aimed to estimate the proportion of HBV-associated" exact="cirrhosis" post="and HCC attributable to HDV. Materials and methods Outcomes"/>
  <result pre="prevalence in the 6 World Health Organisation (WHO) regions. The" exact="primary" post="outcome was the prevalence of total or IgG anti-HDV"/>
  <result pre="Organisation (WHO) regions. The primary outcome was the prevalence of" exact="total" post="or IgG anti-HDV among HBsAg-positive people. The prevalence of"/>
  <result pre="for HBsAg and anti-HDV based on assays employing PCR. The" exact="secondary" post="outcome was the estimation of the population attributable fraction"/>
  <result pre="population attributable fraction (PAF) of HDV among HBsAg-positive persons with" exact="cirrhosis" post="and HCC. We conducted the study in accordance with"/>
  <result pre="on 28 January 2019. The search strategy included synonyms of" exact="hepatitis D" post="and terms describing HDV epidemiology and diagnosis (detailed in"/>
  <result pre="excluded. Studies were also excluded if they used anti-HDV IgM," exact="hepatitis D" post="antigen (HDAg) or HDV RNA as an initial test"/>
  <result pre="that focussed on the following groups were excluded: individuals with" exact="acute" post="hepatitis, returning (repeat) or remunerated blood donors, migrant populations"/>
  <result pre="groups: i) general populations, comprising people tested in community surveys," exact="antenatal" post="clinics, or occupational settings, students, and blood donors (unless"/>
  <result pre="populations, comprising patients reviewed in a hepatology service, regardless of" exact="disease" post="status; and iii) selected population groups, comprising people who"/>
  <result pre="workers (CSW), and people with HCV or HIV. In sub-Saharan" exact="African" post="countries with generalised HIV epidemics (adult prevalence &amp;gt;1% based"/>
  <result pre="clinically evaluated and found not to have evidence of active" exact="chronic hepatitis," post="cirrhosis or HCC. In the analysis of HIV-positive people,"/>
  <result pre="and found not to have evidence of active chronic hepatitis," exact="cirrhosis" post="or HCC. In the analysis of HIV-positive people, comparator"/>
  <result pre="active chronic hepatitis, cirrhosis or HCC. In the analysis of" exact="HIV-positive" post="people, comparator populations were HIV-negative populations or general populations"/>
  <result pre="characteristics and rates of HDV RNA detection using random effects" exact="residual" post="maximum likelihood aggregate level meta-regression with Knapp and Hartung"/>
  <result pre="facilitate interpretation of anti-HDV prevalence estimates among patients diagnosed with" exact="cirrhosis" post="or HCC, we calculated the PAF of HDV for"/>
  <result pre="cirrhosis or HCC, we calculated the PAF of HDV for" exact="cirrhosis" post="and HCC among HBsAg-positive people. We used methodology recommended"/>
  <result pre="ratio].18,19 where OR is used as an approximation for the" exact="disease" post="risk ratio of exposed (anti-HDV positive) vs. non-exposed (anti-HDV"/>
  <result pre="was eligible for inclusion, mainly due to selection bias or" exact="incomplete" post="reporting. We included 282 studies, reporting data from 376"/>
  <result pre="have sex with men, commercial sex workers, and people with" exact="hepatitis C" post="virus or HIV. In sub-Saharan Africa countries with adult"/>
  <result pre="hepatitis C virus or HIV. In sub-Saharan Africa countries with" exact="adult" post="HIV prevalence &amp;gt;1%, HIV populations were included in the"/>
  <result pre="prevalence &amp;gt;1%, HIV populations were included in the general population." exact="Isolated" post="populations were selected sample populations that were considered not"/>
  <result pre="representative of the general population. WHO, World Health Organisation; AFR," exact="African" post="Region; EMR, Eastern Mediterranean Region; EUR, European Region; AMR,"/>
  <result pre="population. WHO, World Health Organisation; AFR, African Region; EMR, Eastern" exact="Mediterranean" post="Region; EUR, European Region; AMR, Region of the Americas;"/>
  <result pre="Pacific Region. Fig.Â 3 Anti-HDV prevalence in HBsAg-positive people. (A)" exact="General" post="populations; (B) Hepatology clinic populations. Each point represents a"/>
  <result pre="Greenland and Rhodes (Greece) (Fig.Â 3, supplementary appendix 11). Only" exact="limited" post="data were available for North America, Latin America and"/>
  <result pre="clinic HBsAg-positive populations, by WHO region. WHO region HBsAg-positive populations" exact="General" post="Hepatology clinics % (95% CI) % (95% CI) AFR"/>
  <result pre="4.09 (3.47â€&quot;4.77) 8.07 (7.50â€&quot;8.64) Global 4.49 (3.57â€&quot;5.68) 16.42 (14.58â€&quot;18.56) AFR," exact="African" post="Region; AMR, Region of the Americas; EMR, Eastern Mediterranean"/>
  <result pre="AFR, African Region; AMR, Region of the Americas; EMR, Eastern" exact="Mediterranean" post="Region; EUR, European Region; SEAR, South-East Asian Region; WHO,"/>
  <result pre="(203â€&quot;877) 285 (184â€&quot;544) 635 (83â€&quot;3,622) 3,617 (2,583â€&quot;4,971) 7,015 (4,994â€&quot;11,109) AFR," exact="African" post="Region; AMR, Region of the Americas; EMR, Eastern Mediterranean"/>
  <result pre="AFR, African Region; AMR, Region of the Americas; EMR, Eastern" exact="Mediterranean" post="Region; EUR, European Region; SEAR, South-East Asian Region; WHO,"/>
  <result pre="World Population Prospects 201916; HBV prevalence estimates from WHO Global" exact="Hepatitis" post="Report 2017.1 Fig.Â 4 Country-level estimates of anti-HDV prevalence"/>
  <result pre="4 Country-level estimates of anti-HDV prevalence among HBsAg-positive people. (A)" exact="General" post="populations; (B) Hepatology clinic populations. Colour indicates HDV seroprevalence."/>
  <result pre="higher among anti-HCV positive people (pooled OR 10.0) and among" exact="HIV-positive" post="people in countries without generalised HIV epidemics (pooled OR"/>
  <result pre="HIV epidemics, the odds of anti-HDV detection were similar in" exact="HIV-positive" post="and HIV-negative people (pooled OR 0.8). Fig.Â 6 Geographic"/>
  <result pre="in HIV-positive and HIV-negative people (pooled OR 0.8). Fig.Â 6" exact="Geographic" post="distribution of HDV genotypesa. aEach circle represents a unique"/>
  <result pre="each 10% increase in anti-HDV prevalence. HDV RNA detection was" exact="lower" post="in general populations relative to hepatology clinic populations (coefficientÂ"/>
  <result pre="CIÂ âˆ’0.33 toÂ âˆ’0.07; pÂ = 0.003). There was also" exact="lower" post="HDV RNA detection in the African region compared to"/>
  <result pre="0.003). There was also lower HDV RNA detection in the" exact="African" post="region compared to other WHO regions (41.3% vs. 64.9%;"/>
  <result pre="estimate of 7.1 million people (95% CI 5.0â€&quot;11.1) had viraemic" exact="infection" post="(HDV RNA positive), representing a general population prevalence of"/>
  <result pre="6â€&quot;8 in Middle Africa (Fig.Â 6). Population attributable fraction for" exact="cirrhosis" post="and HCC among HBsAg-positive people Patients with cirrhosis or"/>
  <result pre="fraction for cirrhosis and HCC among HBsAg-positive people Patients with" exact="cirrhosis" post="or HCC had higher anti-HDV prevalence relative to comparator"/>
  <result pre="our PAF calculation suggested that HDV accounted for 18% of" exact="cirrhosis" post="(95% CI 10â€&quot;26) and 20% of HCC (95% CI"/>
  <result pre="which translates into an estimated prevalence of 0.16% in the" exact="total" post="population. This represents an estimated 12 million people with"/>
  <result pre="an estimated 12 million people with serological evidence of HDV" exact="infection" post="globally. The geographic distribution of HDV infection is heterogeneous,"/>
  <result pre="evidence of HDV infection globally. The geographic distribution of HDV" exact="infection" post="is heterogeneous, with particularly high prevalence reported in Mongolia,"/>
  <result pre="CSWs and MSM, and between anti-HDV prevalence and HCV or" exact="HIV infection," post="which may be secondary to shared transmission routes. These"/>
  <result pre="anti-HDV prevalence and HCV or HIV infection, which may be" exact="secondary" post="to shared transmission routes. These data are useful to"/>
  <result pre="priorities about HDV testing. Interventions that prevent HBV and HCV" exact="infection" post="should also be effective in preventing HDV, including immunization"/>
  <result pre="should also be effective in preventing HDV, including immunization against" exact="hepatitis" post="B and harm reduction strategies in PWID.[25], [26], [27]"/>
  <result pre="estimates in our study consider individuals living in regions with" exact="limited" post="or no data for anti-HDV prevalence. To do so"/>
  <result pre="of additional data to inform epidemiological estimates for regions with" exact="limited" post="data represents a research priority. Unbiased ascertainment of anti-HDV"/>
  <result pre="hepatology clinic may be the result of patients developing characteristics" exact="of liver" post="disease. The resulting population may therefore be more likely"/>
  <result pre="clinic may be the result of patients developing characteristics of" exact="liver disease." post="The resulting population may therefore be more likely to"/>
  <result pre="of these issues and as a result we estimate a" exact="lower" post="anti-HDV prevalence among the general population and provide a"/>
  <result pre="anti-HDV prevalence may be low in children, due to the" exact="absence of" post="specific risk factors and a short duration of risk"/>
  <result pre="due to the absence of specific risk factors and a" exact="short" post="duration of risk exposure. Global estimates for HBV prevalence"/>
  <result pre="of risk exposure. Global estimates for HBV prevalence are significantly" exact="lower" post="among children, largely as a result of HBV vaccination,"/>
  <result pre="relative to 3.5% among the general population globally.1 Accordingly, HDV" exact="infection" post="is expected to be uncommon in children and to"/>
  <result pre="provided a provisional estimate of viraemic, HDV RNA-positive individuals. A" exact="limited" post="number of studies used HDV RNA detection for confirmation"/>
  <result pre="studies used HDV RNA detection for confirmation of a current" exact="infection" post="in participants with anti-HDV; in these studies, the pooled"/>
  <result pre="for HDV RNA represent a significantly smaller sample size with" exact="limited" post="representation from some regions and the estimate of viraemic"/>
  <result pre="limited representation from some regions and the estimate of viraemic" exact="infections" post="should therefore be considered provisional. HDV RNA detection was"/>
  <result pre="infections should therefore be considered provisional. HDV RNA detection was" exact="lower" post="in general populations relative to hepatology clinic populations, and"/>
  <result pre="may reflect the higher pre-test probability of a current HDV" exact="infection" post="in HBsAg-positive people who underwent HDV testing in hepatology"/>
  <result pre="historical performance issues and particular difficulties with the detection of" exact="African" post="genotypes 5â€&quot;8.9 With concerted efforts to improve and standardise"/>
  <result pre="characteristics of anti-HDV tests are lacking and would be informative." exact="Limited" post="data suggests a potential for false negative anti-HDV ELISA"/>
  <result pre="is a broader problem. Estimations of the global burden of" exact="disease" post="from viral hepatitis have not previously considered HDV,30 and"/>
  <result pre="broader problem. Estimations of the global burden of disease from" exact="viral hepatitis" post="have not previously considered HDV,30 and HDV epidemiology and"/>
  <result pre="problem. Estimations of the global burden of disease from viral" exact="hepatitis" post="have not previously considered HDV,30 and HDV epidemiology and"/>
  <result pre="hepatitis have not previously considered HDV,30 and HDV epidemiology and" exact="disease" post="control are not considered in the current Global Health"/>
  <result pre="not considered in the current Global Health Sector Strategy for" exact="Viral" post="Hepatitis.27 We estimated that, globally, between 1 in 5,"/>
  <result pre="between 1 in 5, to 1 in 6 cases of" exact="cirrhosis" post="or HCC among people with hepatitis B are attributable"/>
  <result pre="in 6 cases of cirrhosis or HCC among people with" exact="hepatitis" post="B are attributable to HDV infection, indicating that hepatitis"/>
  <result pre="with hepatitis B are attributable to HDV infection, indicating that" exact="hepatitis D" post="may be an important contributor to liver disease. It"/>
  <result pre="indicating that hepatitis D may be an important contributor to" exact="liver disease." post="It should be noted that there was a paucity"/>
  <result pre="a paucity of studies reporting anti-HDV prevalence among people with" exact="cirrhosis" post="and HCC from some regions (including the South-East Asia"/>
  <result pre="based on ascertainment of anti-HDV prevalence among individuals diagnosed with" exact="cirrhosis" post="and HCC from cross-sectional studies. These may include individuals"/>
  <result pre="may include individuals with early compensated cirrhosis. Since HDV accelerates" exact="disease" post="progression, HDV may have an even greater attributable fraction"/>
  <result pre="have an even greater attributable fraction of HBV-associated mortality from" exact="cirrhosis" post="and HCC. As to the long-term impact of HDV"/>
  <result pre="long-term impact of HDV RNA positivity on the risk of" exact="cirrhosis" post="and HCC, we are limited by the available data,"/>
  <result pre="positivity on the risk of cirrhosis and HCC, we are" exact="limited" post="by the available data, which very rarely include longitudinal"/>
  <result pre="lack of data. In summary, the data indicate that HDV" exact="infection" post="is common among HBsAg-positive people in the general population"/>
  <result pre="and that HDV is responsible for a substantial proportion of" exact="cirrhosis" post="and HCC among HBsAg-positive people. HDV infection should be"/>
  <result pre="substantial proportion of cirrhosis and HCC among HBsAg-positive people. HDV" exact="infection" post="should be considered in all patients with chronic HBV"/>
  <result pre="people. HDV infection should be considered in all patients with" exact="chronic" post="HBV infection. Routine HDV ascertainment in clinical settings is"/>
  <result pre="infection.[29], [30], [31], [32] If all people newly diagnosed with" exact="chronic" post="HBV infection had a routine reflex test for anti-HDV,"/>
  <result pre="[31], [32] If all people newly diagnosed with chronic HBV" exact="infection" post="had a routine reflex test for anti-HDV, surveillance and"/>
  <result pre="routine reflex test for anti-HDV, surveillance and ascertainment of HDV-related" exact="disease" post="would be improved. Public health agencies may want to"/>
  <result pre="improved. Public health agencies may want to report on HDV" exact="infection" post="and implement activities to mitigate the risk of HDV"/>
  <result pre="health surveys, would be useful in areas with sparse data." exact="Hepatitis" post="D is widely distributed but neglected disease. A better"/>
  <result pre="better description of the role that HDV plays in causing" exact="liver disease," post="better efforts to improve epidemiological data collection, ascertainment of"/>
  <result pre="help in mounting an effective public health response. Abbreviations AFR," exact="African" post="Region; AMR, Region of the Americas; CSW, commercial sex"/>
  <result pre="Region of the Americas; CSW, commercial sex workers; EMR, Eastern" exact="Mediterranean" post="Region; EUR, European Region; HCC, hepatocellular carcinoma; MSM, men"/>
  <result pre="sex workers; EMR, Eastern Mediterranean Region; EUR, European Region; HCC," exact="hepatocellular carcinoma;" post="MSM, men who have sex with men; OR, odds"/>
  <result pre="forms for further details. References References 1collab: World Health OrganizationGlobal" exact="Hepatitis" post="Report2017WHOGeneva, Switzerland 2collab: Polaris Observatory CollaboratorsGlobal prevalence, treatment, and"/>
  <result pre="Switzerland 2collab: Polaris Observatory CollaboratorsGlobal prevalence, treatment, and prevention of" exact="hepatitis" post="B virus infection in 2016: a modelling studyLancet Gastroenterol"/>
  <result pre="Polaris Observatory CollaboratorsGlobal prevalence, treatment, and prevention of hepatitis B" exact="virus infection" post="in 2016: a modelling studyLancet Gastroenterol Hepatol3201838340329599078 3MokdadA.A.LopezA.D.ShahrazS.LozanoR.MokdadA.H.StanawayJ.Liver cirrhosis"/>
  <result pre="Observatory CollaboratorsGlobal prevalence, treatment, and prevention of hepatitis B virus" exact="infection" post="in 2016: a modelling studyLancet Gastroenterol Hepatol3201838340329599078 3MokdadA.A.LopezA.D.ShahrazS.LozanoR.MokdadA.H.StanawayJ.Liver cirrhosis"/>
  <result pre="virus infection in 2016: a modelling studyLancet Gastroenterol Hepatol3201838340329599078 3MokdadA.A.LopezA.D.ShahrazS.LozanoR.MokdadA.H.StanawayJ.Liver" exact="cirrhosis" post="mortality in 187 countries between 1980 and 2010: a"/>
  <result pre="and 2010: a systematic analysisBMC Med12201414525242656 4AkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.collab: Global Burden of" exact="Disease" post="Liver Cancer CollaborationThe burden of primary liver cancer and"/>
  <result pre="a systematic analysisBMC Med12201414525242656 4AkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.collab: Global Burden of Disease Liver" exact="Cancer" post="CollaborationThe burden of primary liver cancer and underlying etiologies"/>
  <result pre="4AkinyemijuT.AberaS.AhmedM.AlamN.AlemayohuM.A.AllenC.collab: Global Burden of Disease Liver Cancer CollaborationThe burden of" exact="primary" post="liver cancer and underlying etiologies from 1990 to 2015"/>
  <result pre="Global Burden of Disease Liver Cancer CollaborationThe burden of primary" exact="liver cancer" post="and underlying etiologies from 1990 to 2015 at the"/>
  <result pre="Burden of Disease Liver Cancer CollaborationThe burden of primary liver" exact="cancer" post="and underlying etiologies from 1990 to 2015 at the"/>
  <result pre="regional, and national level: results from the global burden of" exact="disease" post="study 2015JAMA Oncol320171683169128983565 5HughesS.A.WedemeyerH.HarrisonP.M.Hepatitis delta virusLancet3782011738521511329 6Botelho-SouzaL.F.VasconcelosM.P.A.Dos SantosA.O.SalcedoJ.M.V.VieiraD.S.Hepatitis delta:"/>
  <result pre="6Botelho-SouzaL.F.VasconcelosM.P.A.Dos SantosA.O.SalcedoJ.M.V.VieiraD.S.Hepatitis delta: virological and clinical aspectsVirol J14201717728903779 7FattovichG.GiustinaG.ChristensenE.PantalenaM.ZagniI.RealdiG.Influence of" exact="hepatitis delta" post="virus infection on morbidity and mortality in compensated cirrhosis"/>
  <result pre="delta: virological and clinical aspectsVirol J14201717728903779 7FattovichG.GiustinaG.ChristensenE.PantalenaM.ZagniI.RealdiG.Influence of hepatitis delta" exact="virus infection" post="on morbidity and mortality in compensated cirrhosis type B."/>
  <result pre="virological and clinical aspectsVirol J14201717728903779 7FattovichG.GiustinaG.ChristensenE.PantalenaM.ZagniI.RealdiG.Influence of hepatitis delta virus" exact="infection" post="on morbidity and mortality in compensated cirrhosis type B."/>
  <result pre="hepatitis delta virus infection on morbidity and mortality in compensated" exact="cirrhosis" post="type B. The European Concerted Action on Viral Hepatitis"/>
  <result pre="delta virus infection on morbidity and mortality in compensated cirrhosis" exact="type B." post="The European Concerted Action on Viral Hepatitis (Eurohep)Gut46200042042610673308 8KushnerT.SerperM.KaplanD.E.Delta"/>
  <result pre="in compensated cirrhosis type B. The European Concerted Action on" exact="Viral" post="Hepatitis (Eurohep)Gut46200042042610673308 8KushnerT.SerperM.KaplanD.E.Delta hepatitis within the veterans affairs medical"/>
  <result pre="compensated cirrhosis type B. The European Concerted Action on Viral" exact="Hepatitis" post="(Eurohep)Gut46200042042610673308 8KushnerT.SerperM.KaplanD.E.Delta hepatitis within the veterans affairs medical system"/>
  <result pre="B. The European Concerted Action on Viral Hepatitis (Eurohep)Gut46200042042610673308 8KushnerT.SerperM.KaplanD.E.Delta" exact="hepatitis" post="within the veterans affairs medical system in the United"/>
  <result pre="States: prevalence, risk factors, and outcomesJÂ Hepatol63201558659225962883 9Le GalF.BrichlerS.SahliR.ChevretS.GordienE.First international" exact="external" post="quality assessment for hepatitis delta virus RNA quantification in"/>
  <result pre="and outcomesJÂ Hepatol63201558659225962883 9Le GalF.BrichlerS.SahliR.ChevretS.GordienE.First international external quality assessment for" exact="hepatitis delta" post="virus RNA quantification in plasmaHepatology6420161483149427530084 10KohC.HellerT.GlennJ.S.Pathogenesis of and new"/>
  <result pre="RNA quantification in plasmaHepatology6420161483149427530084 10KohC.HellerT.GlennJ.S.Pathogenesis of and new therapies for" exact="hepatitis" post="DGastroenterology156201846147630342879 11StockdaleA.J.ChapondaM.BeloukasA.PhillipsR.O.MatthewsP.C.PapadimitropoulosA.Prevalence of hepatitis D virus infection in sub-Saharan"/>
  <result pre="10KohC.HellerT.GlennJ.S.Pathogenesis of and new therapies for hepatitis DGastroenterology156201846147630342879 11StockdaleA.J.ChapondaM.BeloukasA.PhillipsR.O.MatthewsP.C.PapadimitropoulosA.Prevalence of" exact="hepatitis D" post="virus infection in sub-Saharan Africa: a systematic review and"/>
  <result pre="and new therapies for hepatitis DGastroenterology156201846147630342879 11StockdaleA.J.ChapondaM.BeloukasA.PhillipsR.O.MatthewsP.C.PapadimitropoulosA.Prevalence of hepatitis D" exact="virus infection" post="in sub-Saharan Africa: a systematic review and meta-analysisLancet Glob"/>
  <result pre="new therapies for hepatitis DGastroenterology156201846147630342879 11StockdaleA.J.ChapondaM.BeloukasA.PhillipsR.O.MatthewsP.C.PapadimitropoulosA.Prevalence of hepatitis D virus" exact="infection" post="in sub-Saharan Africa: a systematic review and meta-analysisLancet Glob"/>
  <result pre="and meta-analysisLancet Glob Health52017e992e100328911765 12BrichlerS.Le GalF.Neri-PintoF.MansourW.RoulotD.LapercheS.Serological and molecular diagnosis of" exact="hepatitis delta" post="virus infection: results of a French national quality control"/>
  <result pre="World Health OrganizationGlobal and country estimates of immunization coverage and" exact="chronic" post="HBV infection2017WHOGeneva, Switzerland 18collab: World Health OrganizationConsolidated strategic information"/>
  <result pre="infection2017WHOGeneva, Switzerland 18collab: World Health OrganizationConsolidated strategic information guidelines for" exact="viral" post="hepatitis: planning and tracking progress towards elimination2019WHOGeneva, Switzerland 19MiettinenO.S.Proportion"/>
  <result pre="hepatitis: planning and tracking progress towards elimination2019WHOGeneva, Switzerland 19MiettinenO.S.Proportion of" exact="disease" post="caused or prevented by a given exposure, trait or"/>
  <result pre="trait or interventionAm J Epidemiol9919743253324825599 20SchweitzerA.HornJ.MikolajczykR.T.KrauseG.OttJ.J.Estimations of worldwide prevalence of" exact="chronic hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="or interventionAm J Epidemiol9919743253324825599 20SchweitzerA.HornJ.MikolajczykR.T.KrauseG.OttJ.J.Estimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="outcomeStat Med2020013875388911782040 23SchwarzerG.Meta: an R package for meta-analysisRÂ News720074045 24WedemeyerH.NegroF.Devil" exact="hepatitis" post="D: an orphan disease or largely underdiagnosed?Gut68201938138230368454 25StockdaleA.J.KreuelsB.HenrionM.R.Y.GiorgiE.KyomuhangiI.GerettiA.M.Hepatitis D"/>
  <result pre="R package for meta-analysisRÂ News720074045 24WedemeyerH.NegroF.Devil hepatitis D: an orphan" exact="disease" post="or largely underdiagnosed?Gut68201938138230368454 25StockdaleA.J.KreuelsB.HenrionM.R.Y.GiorgiE.KyomuhangiI.GerettiA.M.Hepatitis D prevalence: problems with extrapolation"/>
  <result pre="novel quantitative microarray antibody capture assay identifies an extremely high" exact="hepatitis delta" post="virus prevalence among hepatitis B virus-infected mongoliansHepatology6620171739174927880976 27collab: World"/>
  <result pre="assay identifies an extremely high hepatitis delta virus prevalence among" exact="hepatitis" post="B virus-infected mongoliansHepatology6620171739174927880976 27collab: World Health OrganizationGlobal health sector"/>
  <result pre="virus-infected mongoliansHepatology6620171739174927880976 27collab: World Health OrganizationGlobal health sector strategy on" exact="viral hepatitis" post="2016-20212016WHOGeneva, Switzerland 28LutterkortG.L.WrankeA.HengstJ.YurdaydinC.StiftJ.BremerB.Viral dominance patterns in chronic hepatitis delta"/>
  <result pre="mongoliansHepatology6620171739174927880976 27collab: World Health OrganizationGlobal health sector strategy on viral" exact="hepatitis" post="2016-20212016WHOGeneva, Switzerland 28LutterkortG.L.WrankeA.HengstJ.YurdaydinC.StiftJ.BremerB.Viral dominance patterns in chronic hepatitis delta"/>
  <result pre="strategy on viral hepatitis 2016-20212016WHOGeneva, Switzerland 28LutterkortG.L.WrankeA.HengstJ.YurdaydinC.StiftJ.BremerB.Viral dominance patterns in" exact="chronic hepatitis" post="delta determine early response to interferon alpha therapyJÂ Viral"/>
  <result pre="on viral hepatitis 2016-20212016WHOGeneva, Switzerland 28LutterkortG.L.WrankeA.HengstJ.YurdaydinC.StiftJ.BremerB.Viral dominance patterns in chronic" exact="hepatitis delta" post="determine early response to interferon alpha therapyJÂ Viral Hepat2520181384139429888837"/>
  <result pre="chronic hepatitis delta determine early response to interferon alpha therapyJÂ" exact="Viral" post="Hepat2520181384139429888837 29YurdaydinC.New treatment options for delta virus: is a"/>
  <result pre="treatment options for delta virus: is a cure in sight?JÂ" exact="Viral" post="Hepat26201961862630771261 30WedemeyerH.PortK.DeterdingK.WrankeA.KirschnerJ.BrunoB.PS-039 - a phase 2 dose-escalation study of"/>
  <result pre="2 dose-escalation study of lonafarnib plus ritonavir in patients with" exact="chronic hepatitis" post="D: final results from the Lonafarnib with ritonavir in"/>
  <result pre="dose-escalation study of lonafarnib plus ritonavir in patients with chronic" exact="hepatitis" post="D: final results from the Lonafarnib with ritonavir in"/>
  <result pre="B in combination with Peg-Interferon alpha 2a in patients with" exact="chronic" post="HBV/HDV co-infectionHepatology68201811A 32BazinetM.PÃ¢nteaV.CebotarescuV.CojuhariL.JimbeiP.AlbrechtJ.Treatment of HBV/HDV co-infection with REP-2139 and"/>
 </snippets>
</snippetsTree>
